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Olson et al. (2015) propose that some hydroxamic acid-based small molecules, already in clinical use as
histone deacetylase inhibitors, may protect against oxidative stress through a direct chemical reaction of
dismutation of hydrogen peroxide into water.The equilibrium between acetylation and
deacetylation is a key controller of protein
function. Thus, it is no surprise that
the balance between acetylation and
deacetylation levels is lost in several
pathologies, including cancer and degen-
erative diseases. Protein acetylation is
carried out by enzymes with acetyltrans-
ferase activity and can be reverted by de-
acetylases. For historical reasons, these
enzymes are commonly termed ‘‘histone
acetylases’’ (HATs) or ‘‘histone deacety-
lases’’ (HDACs), though it would be more
appropriate to call them ‘‘protein’’ or
‘‘lysine acetylases/deacetylases.’’ HDACs
are categorized into four different classes,
I through IV, and most of them, with
the exception of the class III ‘‘sirtuins,’’
are evolutionarily related metalloenzymesFigure 1. A Schematic View of the Activity of Some Hydroxamic
Acid-Based HDAC Inhibitors, Such as Panobinostat/LBH-589
(A) At concentrations below 1 mM, close to those used in clinic, panobinostat
acts by inhibiting HDACs, which leads to increased levels of histone acetyla-
tion and transcriptional changes that result in enhanced protection from
oxidative stress. HDACi, HDAC inhibitor.
(B) At concentrations above 1 mM, panobinostat and some other hydroxamic
acid-based HDAC inhibitors exhibit an additional activity that protect against
oxidative stress as they directly catalyze conversion of hydrogen peroxide to
water.(Lombardi et al., 2011).
Pharmacological modula-
tion of HATs/HDACs has
been at the forefront of drug
discovery, and several HDAC
inhibitors have been already
approved for selected indi-
cations in oncology (Falken-
berg and Johnstone, 2014).
Structurally, most HDAC
inhibitors are not selective
and act equally well against
several HDACs. These com-
pounds share a common
hydroxamic moiety, required
to form chelate interactions
with the metal in the HDAC
catalytic site. More recently
identified HDAC inhibitors
have distinct chemical prop-
erties and show higher selec-
tivity (Falkenberg and John-
stone, 2014).The list of diseases for which oxidative
stress plays a role in pathogenesis
continues to increase, and as that list
grows so does the interest in neutralizing
the oxidative stress. One strategy for
diminishing oxidative stress that seems
attractive is through potentiation of
natural antioxidant defenses, especially
in cancer, aging, and degenerative dis-
eases. In cells, enzymes superoxide
dismutase and catalase catalytically elim-
inate superoxide and hydrogen peroxide
and decrease oxidative stress. This
inspired development of several low-
molecular-weight synthetic compounds
that mimic the function of superoxide dis-
mutase and catalase (Rong et al., 1999).
HDAC inhibitors have been proposed to
protect against oxidative stress throughChemistry & Biology 22, April 23, 2015their HDAC inhibitory activity and regu-
lation of transcription (Falkenberg and
Johnstone, 2014). However, Olson et al.
(2015) studied neuronal cell death
induced by hydrogen peroxide, and they
observed that hydroxamic-based HDAC
inhibitors were able to protect against
cell death irrespective of their potency
shown in biochemical assays in vitro
against recombinant HDACs. Strikingly,
supposedly structurally related controls
(i.e., hydroxamic acids devoid of HDAC
inhibitory activity) were still able to
exert neuroprotection. Consistent with
an HDAC-independent mechanism, the
activity was not dependent on ongoing
transcription and translation, but was
rather based on the ability of hydroxamic
acids to chelate metals: indeed, com-ª2015 Elsepounds unable to bind iron
were inactive in the neuronal
cell death assay. Metal chela-
tion, however, was not suffi-
cient to provide neuroprotec-
tive properties, since some
compounds, though able to
bind iron, were inactive in
the cell assay. Indeed, the
most consistent correlation
with the neuroprotection cell
assay is found when the au-
thors tested the hypothesis
that the cell-active hydroxa-
mic acids were acting in
complex with iron as catalase
mimetics, with a stronger
potency than commercially
available compounds (EUK
134). Differences in the ability
to trigger hydrogen peroxide
dismutation of distinct HDAC
inhibitors could be correlatedvier Ltd All rights reserved 431
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Previewswith energies of highest occupied
(HOMO) and lowest unoccupied (LUMO)
molecular orbital and electronegativities
of the involved chemical species (Suksri-
chavalit et al., 2008).
Do these findings imply that we need
to revisit our thinking about the mecha-
nism of action of at least some hydroxa-
mic based HDAC inhibitors, including
recently FDA-approved panobinostat
(LBH-589), and consider that they might
act also through HDAC-independent,
catalase mimetic mechanisms? One
important point to keep in mind about
Olson et al.’s study is that all of the cell
based assays were performed in the
presence of high concentrations of com-
pounds (usually 30 mM). These concentra-
tions might not be relevant from a clinical
perspective, given that, for example, in
the case of panobinostat, this concentra-
tion is >10,000 higher than the biochem-
ical IC50 calculated in vitro against
HDACs. By itself, this does not neces-
sarily mean that we should not think very
carefully about whether a systematic
re-evaluation of hydroxamic based
HDAC inhibitors and their HDAC-inde-432 Chemistry & Biology 22, April 23, 2015 ªpendent, catalase mimetic mechanisms
is needed. But we pose that the critical
question to keep in mind is whether the
high concentrations need to achieve
high catalase mimetic efficiency can be
reached in vivo in patients, for example,
in a chronic treatment setting. We think
that this is unlikely because dose-limiting
toxicity is readily achieved for all clinically
tested HDAC inhibitors at doses well
below the ‘‘catalase mimetic’’ range
(Figure 1). For panobinostat, clinically
used doses reachmaximum values below
1 mM (Anne et al., 2013). Interestingly,
Olson et al. (2015) suggest that HDAC
inhibitors may act through a dual mecha-
nism against oxidative stress: (1) inhibition
of HDACs at low concentrations and (2)
catalase mimetics at high concentrations.
On the other hand, we think that the
only clinically relevant concentrations for
HDAC inhibitors are the ‘‘low’’ ones and
that catalase mimetic mechanism might
be of importance for those interested in
exploring effects of HDAC inhibitors and
oxidative stress in cell-based settings.
The work by Olson et al. (2015) opens up
several interesting opportunities for future2015 Elsevier Ltd All rights reservedresearch. For example, it might be inter-
esting to design new hydroxamic-acid-
based compounds that would exhibit
catalase mimetic activity at much lower
concentrations. Those compounds would
be more clinically attractive strategy to
protect from oxidative stress via HDAC-
dependent and -independent routes.
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The inflammatory response is a critical component of the immune system that is activated by stimuli such as
cytokines, foreign DNA, RNA, or other harmful substances. Krukenberg et al. (2015) identify poly(ADP-ribose)
as a new signaling molecule that activates inflammation, thus providing yet another mechanism by which
PARPs are involved in cellular stress responses.Multicellular organisms are in constant
danger from harmful foreign substances,
chemicals, and pathogens. Multiple
defense mechanisms have therefore
evolved to counter these threats. In mam-
mals, the innate immune system acts
as the front line defense to detect these
stimuli and to mount an initial response
that puts the immune system into a state
of alert (Janeway and Medzhitov, 2002).Stimuli such as foreign DNA, RNA, or
other harmful substances are detected
by macrophages that are subsequently
activated. Upon activation, the macro-
phages secret cytokines that attract im-
mune cells to the site of danger, activate
immune cells, and present them with the
molecular signature of the threat. Stimuli
that activate macrophages are called
PAMP (pathogen-associated molecularpattern) when derived from pathogens
(e.g., DNA, RNA, or other molecules) or
DAMP (damage-associated molecular
pattern) during noninfectious inflamma-
tory responses (e.g., harmful substances
or normally intracellular host DNA, RNA,
or proteins) (Tang et al., 2012). These sig-
nals are primarily recognized by pattern
recognition receptors (PRR) such as
members of the toll-like receptor (TLR)
